Abstract The renin-angiotensin system (RAS) plays a critical role in kidney development. Mutations in the genes encoding components of the RAS cause a spectrum of congenital abnormalities of the kidney and renal collecting system, ranging from hypoplasia of the renal medulla and hydronephrosis in mice to renal tubular dysgenesis in humans. However, the mechanisms by which an intact RAS controls proper renal system development and how aberrations in the RAS result in abnormal kidney and renal collecting system development are poorly understood. The renal collecting system originates from the ureteric bud (UB). A number of transcription and growth factors regulate UB branching morphogenesis to ultimately form the ureter, pelvis, calyces, medullary, and cortical collecting ducts. Importantly, UB morphogenesis is a key developmental process that controls organogenesis of the entire metanephros. This review emphasizes emerging insights into the role for the RAS in UB morphogenesis and explores the mechanisms whereby RAS regulates this important process. A conceptual framework derived from recent work indicates that cooperation between the angiotensin II AT 1 receptor and receptor tyrosine kinase signaling performs essential functions during renal collecting system development via control of UB branching morphogenesis.
Introduction
Branching morphogenesis of the ureteric bud (UB) is a key developmental process that controls not only formation of the renal collecting system but also organogenesis of the entire metanephros. Derangements in UB morphogenesis cause a spectrum of congenital abnormalities of the kidney and urinary tract (CAKUT). Many forms of CAKUT have a genetic basis and are associated with hereditary human syndromes [1] . The inheritance pattern of some nonsyndromic cases of CAKUT (e.g. autosomal-dominant or recessive polycystic kidney disease) is well known [2] . In other nonsyndromic forms of CAKUT (e.g. obstructive uropathy, vesico-ureteral reflux, kidney hypodysplasia, duplex kidneys), the hereditary and molecular mechanisms remain to be determined.
Mutations in the genes encoding components of the renin-angiotensin system (RAS) or pharmacological inhibition of RAS in animals or humans cause diverse malformations of the renal excretory system that include papillary and medullary hypodysplasia, hydronephrosis, collapsed collecting ducts, aberrant UB budding, duplicated collecting system, and urinary concentrating defect [3] [4] [5] [6] [7] [8] [9] [10] . Since CAKUT are the major cause of renal failure in childhood [11] , identification of the molecular mechanisms that lead to diverse forms of CAKUT under conditions of disrupted RAS has important clinical implications.
Overview of metanephric kidney development
The development of the metanephric kidney begins when the nephric duct (ND) gives rise to the UB on embryonic day (E) 10.5 in mice and E28 in humans [12] . Ureteric bud outgrowth from the ND is followed by its repetitive branching, growth and remodeling, a process called branching morphogenesis (Fig. 1) , to eventually form the renal collecting system [13, 14] . Initial generations of UB branches will be remodeled into the ureter, renal pelvis, and calyces, whereas subsequent generations of UB branches will give rise to collecting ducts. The ureter will translocate from the ND to fuse with the bladder [15, 16] . Collecting ducts will subsequently undergo patterning to contribute importantly to the renal papilla and medulla. Each UB tip is capable of inducing the adjacent metanephric mesenchyme to undergo mesenchymal-to-epithelial transition (MET) and form nephrons (from the glomerulus through the distal tubule) [13] . Even subtle defects in the efficiency of UB branching result in a significant decrease in nephron endowment [17] . In turn, decreased nephron endowment is linked to renal hypodysplasia, CAKUT, hypertension, and eventual progression to chronic renal failure [11, 18, 19] .
Growth factors in UB morphogenesis
Uteric bud initiation, branching, and patterning is regulated by reciprocal interactions of transcription and growth factors expressed in metanephric mesenchyme, stroma, angioblasts, and UB itself [20] (Fig. 2) . Signals from the metanephric mesenchyme, stroma and angioblasts induce the UB to originate from the ND, invade the mesenchyme, and undergo branching morphogenesis. Metanephric mesenchymal cells secrete glial-derived neurotrophic factor (GDNF) which interacts with the c-Ret tyrosine kinase receptor expressed in the UB tip cells to induce branching [21] . Expression of GDNF or c-Ret is activated by paired box 2 (Pax-2), a transcription factor present in the metanephric mesenchyme [22, 23] . Stromal cells provide critical signals to regulate UB branching via forkhead/ winged helix transcription factor d1 (Foxd1) or retinoic acid. The Foxd1 or combined retinoic acid receptor (RAR) α/β2 deficiency in mice compromises UB branching [24, 25] . Interestingly, UB tip cells in RARα/β2-deficient mice express less c-Ret, and genetic overexpression of c-Ret in these mice rescues UB branching and stromal patterning. Thus, not only stroma-derived signals regulate UB morphogenesis, but c-Ret-dependent UB output is important in stromal development. In addition, UB signaling is critical for the induction and maintenance of nephrogenesis. For example, conditional inactivation of Wnt9b, normally expressed in the UB epithelium, leads to defects in the formation of renal vesicles [26] . This is accompanied by the absence of the early nephron markers, such as Wnt4, Fgf8, and Pax8. Uteric bud branching in Wnt9b-deficient mice is also disrupted, possibly due to decreased levels of GDNF in the mesenchyme and of Wnt11-in the UB tip cell domain [26] .
Wnt11 cooperates with the GDNF/c-Ret pathway to regulate UB morphogenesis. Metanephroi of Wnt11-null mice express less GDNF and have fewer nephrons and UB branches than their wild-type littermates [27] . Moreover, cRet and Wnt11 interact genetically to induce UB branching. Thus, Wnt11 acts as a critical component of the GDNF/cRet/Wnt11 signaling loop to stimulate UB branching [28] . Augmenting effects of the GDNF/c-Ret/Wnt11 pathway on UB development are antagonized by Spry1. Spry1 acts to inhibit c-Ret receptor tyrosine kinase (RTK) activity, prevent expansion of the GDNF and Wnt11 domains, and, therefore, decrease UB branching [28] . Recent studies have demonstrated that Wnt-dependent UB branching is mediated via the canonical β-catenin pathway [29] . Targeted inactivation of β-catenin in UB cell lineage causes decreased expression of transcription factors Emx2, Pax2, and Lim1 followed by downregulation of GDNF/c-Ret/Wnt11 and results in disrupted branching morphogenesis [29] . Stem cell factor (SCF) represents yet another signaling molecule released by the UB. It interacts with RTK c-kit located in In addition to GDNF, a number of other RTK-stimulating growth factors have been shown to regulate UB morphogenesis. While fibroblast growth factors (FGF) 7 and 10 or insulin-like growth factor (IGF-1) promote, TGF-β and activin A inhibit UB budding [32] [33] [34] [35] [36] . Genetic inactivation of FGF7 or FGF10 in mice results in a reduced number of UB branches and medullary collecting ducts and leads to papillary hypodysplasia [32, 34, 35] . Both FGF7 and FGF10 are present in the stroma and bind FGF RTK2, which is expressed exclusively in the UB [37] [38] [39] . Ureteric bud-specific inactivation of the FGF RTK2, but not FGF RTK1, in mice reduces UB branching and nephron number [38] . Epidermal growth factor receptor (EGFR) is expressed in renal collecting ducts [40] . Stimulation of the EGFR by its ligand enhances branching tubule formation in mouse inner medullary collecting duct (IMCD-3) cells grown in threedimensional collagen matrix gels in vitro [41] . In vivo studies demonstrate that EGFR-mutant mice have abnormal collecting ducts [42] . As RTK-stimulating growth factors, GDNF, FGF7/FGF10, or EGF may signal via shared downstream pathways to stimulate UB branching. Moreover, the GDNF/c-Ret-dependent pathway can be bypassed by other morphogenetic growth factors. In this regard, the addition of FGF7 along with activin A, an inhibitor of the TGF-β superfamily, induces branching in isolated nephric ducts in vitro [43] . Therefore, there is a functional redundancy between growth factor signaling during UB morphogenesis.
Bone morphogenetic proteins (BMP), members of the TGF-β superfamily, play an important role in UB morphogenesis. The BMP growth factors signal via activin-like II-growth factor cross-talk in ureteric bud morphogenesis. Metanephric mesenchyme and stroma interact reciprocally with the ureteric bud (UB) and angioblasts to form the metanephros. Multiple gene regulatory networks have been shown to regulate UB elongation, branching, and nephron formation. Signaling molecule Slit2 and its receptor Robo2, forkhead/winged helix transcription factors C1 and C2 (FoxC1/C2), bone morphogenetic protein (BMP) 4 and Ang II AT 2 R act to restrict glial-derived neurotrophic factor (GDNF) expression anteriorly and specify the correct site of UB outgrowth from the nephric duct [47, 58] . The GDNF/c-Ret/Wnt11 pathway is the major positive regulator of UB development [22] . Stromal factors Foxd1, retinoic acid receptor (Rar) β2, BMP4, fibroblast growth factors (FGF) 7 and 10 play an essential role in UB morphogenesis [78] . FGF7/10 act via FGF receptor tyrosine kinase 2 (RTK2). Angiotensinogen (AGT) and Ang II are emerging stromal factors that regulate UB morphogenesis [61] . Since renin-expressing cells are present in the stroma on E12 [62] , co-localization of AGT [61] and renin in the stroma suggests that Ang II is generated around the UB and acts in a paracrine manner on the AT 1 R and AT 2 R expressed in the UB to regulate branching. Ang II AT 1 R cross-talks with the GDNF/cRet/Wnt11 pathway and epidermal growth factor receptor (EGFR). Stimulation of the AT 1 R by Ang II inhibits Spry1 gene expression and thereby relieves inhibition of signaling via the GDNF/c-Ret/Wnt11 pathway [67] . In addition, Ang II enhances tyrosine phosphorylation of EGFR in UB cells [63] . Inhibition of EGFR tyrosine kinase activity abrogates Ang II-induced UB morphogenesis [63] . Coupling of Ang II with the AT 2 R upregulates paired box 2 (Pax2) and stimulates UB branching [64] . Stem cell factor (SCF) is expressed in the UB and acts via its receptor c-kit to induce GDNF expression in the metanephric mesenchyme and thereby modulate UB branching [31] kinase (ALK) type I serine/threonine kinase receptors coupled to downstream cytoplasmic signal-transducing Smad proteins [44] . BMP2, BMP4, and BMP7 are most clearly involved in regulating UB branching. Treatment of embryonic kidney explants or isolated UBs with exogenous BMP2, BMP4, or high doses of BMP7 inhibits UB branching in vitro [45] [46] [47] [48] . BMP4 is expressed exclusively in the stroma, and BMP4 +/− embryos exhibit duplicated UBs, suggesting that BMP4 acts to suppress ectopic UB budding [47] . Ureteric bud-specific inactivation of the ALK3 receptor subtype in mice causes aberrant UB and collecting duct morphogenesis, resulting in hypoplasia of the renal medulla [49] . Since these mice exhibit a decrease in the expression of Pax2 in the UB and metanephric mesenchyme, an initial decrease in UB branching may be due, in part, to reduced Pax2-dependent signaling.
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is the principal effector peptide growth factor of the RAS which acts via two major types of G protein-coupled receptors (GPCR): AT 1 R and AT 2 R. AT 1 R is a mitogen for renal vascular, mesangial, and tubular cells [50] . In contrast, AT 2 R inhibits growth and proliferation in mesangial cells [51] . Ang-(1-7) is a newly discovered member of the RAS. It is formed from Ang II by angiotensin-converting enzyme 2 (ACE2) and acts via GPCR Mas to oppose Ang II-AT 1 R-mediated effects [52, 53] . Genetic inactivation of the AT 1 R, AT 2 R, and other RAS components in mice or pharmacologic antagonism of the RAS cause a spectrum of abnormalities in the development of the renal collecting system [3] [4] [5] [6] [7] [8] [9] [10] . Angiotensinogen-, ACE-, or AT 1 R-deficient mice manifest hydronephrosis, hypoplastic medulla, and papilla. Studies from Ichikawa's laboratory have suggested that medullary hypoplasia and hydronephrosis in AT 1 R-deficient mice may be due to a hypoplastic ureteral smooth muscle layer that exhibits impaired peristalsis [54] . Functionally, ACE-and AT 1 R-null animals have a reduced ability to concentrate urine [6, 7] . The use of ACE inhibitors and AT 1 R blockers in humans cause oligohydramnios and anuria [55, 56] . Therefore, these drugs should not be used by pregnant women. AT 2 R-mutant mice demonstrate a decrease in the rate of apoptosis of mesenchymal cells around the nascent UB [57] and increased incidence of duplex ureters and vesicoureteral reflux [58] . Thus, it is conceivable that the absence of timely apoptosis of mesenchymal cells may cause an aberrant UB budding and lead to duplicated ureters. In addition, AT 2 R may act as restricting signal to limit anterior expansion of the GDNF domain (Fig. 2) . The role of the ACE2-Ang-(1-7)-Mas axis in kidney development and UB morphogenesis remains to be determined. However, based on the findings that the ACE2 homolog collectrin is expressed in the UB branches as early as E13 in the mouse [59] and that Ang-(1-7), acting via Mas, inhibits Ang II-induced phosphorylation of MAP kinase in kidney proximal tubular cells [53] , such a role is likely.
Mutations in the genes encoding for angiotensinogen, renin, ACE, or AT 1 R in humans lead to renal tubular dysgenesis (RTD) [10, 60] . In RTD, the renal cortex exhibits a paucity of proximal tubules. In the medulla, collapsed collecting ducts and abundant interstitial fibrosis are observed [60] . Importantly, RTD is characterized by perinatal death due to anuria combined with pulmonary hypoplasia. The more severe outcome in humans than in mice without the functional RAS may be due to the temporal difference in the completion of nephrogenesis. In mice, nephrogenesis is completed 2 weeks after birth, whereas in humans, it is complete at a gestational age of 38 weeks. Collectively, the observed abnormalities in UB/ medullary development imply that UB-derived structures are targets for Ang II actions during metanephric development in both mice and humans.
We recently demonstrated that angiotensinogen and Ang II AT 1 R are present in both the UBs and stroma on E12 in the mouse and that their expression increases progressively from E12 to E16 [61] . Importantly, AT 1 R immunoreactivity is present on both luminal and basolateral aspects of the UB branches. Since renin-producing cells originate from the mesenchyme on E11-E12, at a time when UB branching is just beginning [62] , Ang II may be generated locally in the mesenchyme to act in a paracrine fashion on the adjacent AT 1 R-expressing UBs to regulate branching (Fig. 2) . In accordance with this hypothesis, we further demonstrate that Ang II, acting via the AT 1 R, stimulates UB growth and branching in the intact whole embryonic (E) day E11.5 metanephroi grown ex vivo and studied at 24 and 48 h after Ang II treatment [63] . These findings indicate that Ang II promotes morphogenesis of the renal collecting system. Ang II can stimulate UB branching directly or through an interaction with other transcription and growth factors present in the metanephric mesenchyme, stroma, angioblasts, or the UB that are known to regulate UB morphogenesis (Fig. 2) . For example, Ang II may stimulate Pax2 present in the UB or mesenchyme and thereby enhance UB branching. This possibility is supported by the ability of Ang II to increase Pax2 gene expression in the metanephric kidney [64] . Since such RTK-stimulating growth factors as FGF7 or EGF enhance the ability of GDNF to elicit ectopic UB budding [43] , Ang II may induce UB branching by enhancing the sensitivity of the UB to GDNF, EGF, or FGF7. In addition, Ang II may alter the expression of competence growth factors in favor of UB branching. In keeping with this hypothesis, the renal papilla of angiotensinogen-and AT 1 R-deficient mice exhibits reduced EGF mRNA levels [4] . Moreover, ACE inhibition during neonatal nephrogenesis in the rat decreases IGF-1 mRNA and protein expression in the renal medulla [65] . Both AT 1 R and FGF7 are expressed in the stromal mesenchyme, and Ang II increases FGF7 mRNA levels in luteal cells [66] . These observations indicate that RAS interacts with EGF and IGF-1 and may induce FGF7 during medullary development.
Given that GDNF/c-Ret signaling pathway is a major positive regulator of the UB branching morphogenesis program [22], we recently tested whether Ang II enhances GDNF and c-Ret expression during active UB branching. Treatment with Ang II induced expression of GDNF mRNA in the metanephric mesenchyme [67] . This was accompanied by increased expression of c-Ret and GDNF RTK and of Wnt11, a downstream target of c-Ret signaling, in the UB tip cells. Moreover, Ang II caused preferential proliferation of UB tip cells, whereas inhibition of endogenous AT 1 R signaling inhibited UB tip cell apoptosis [67] . Therefore, Ang II not only induced GDNF/c-Ret expression during the critical period of UB morphogenesis, but also induced mitogenic and prosurvival effects in the UB tip cells leading to UB growth and branching. To determine the mechanism of Ang II-induced upregulation of GDNF/c-Ret signaling, we next examined the effect of Ang II and its AT 1 R on the expression of Spry1, an endogenous inhibitor of c-Ret RTK signaling [28] . Ang II decreased Spry1 in an AT 1 R-dependent manner [67] . These findings indicate that AT 1 R-GDNF/c-Ret cross-talk involves the downregulation of Spry1. This in turn facilitates c-Ret RTK signaling, leading to activation of the GDNF/Ret/Wnt11 positive feedback loop. It is conceivable that Ang II induces focal bursts of proliferation of UB tip cells and, together with decreased apoptosis, plays an important role in the expansion of the ampulla, subsequent branching, and directional bud elongation.
Alternatively or additionally, stimulation of the AT 1 R by its ligand can transactivate RTK to enhance morphogenetic signaling without altering the expression levels of a given positive growth factor or its cognate RTK. To test this hypothesis, we recently investigated the ability of Ang II to transactivate EGFR in UB cells and examined the contribution of EGFR activation to Ang II-induced UB branching. Ang II increased tyrosine phosphorylation of EGFR in UB cells [57] . Moreover, inhibition of EGFR tyrosine kinase activity abrogated Ang II-induced UB branching in the intact metanephros [63] . These findings indicate that cross-talk between the AT 1 R and EGFR is . AT 1 R-and AT 2 R-mediated activation of multiple signaling pathways involving Jak2/STAT [64] , Ras/ERK1/2 [70, 71] , PI3K/Akt [68, 69] , and epidermal growth factor receptor (EGFR) transactivation [63] may stimulate UB cell proliferation, survival, and migration and promote UB morphogenesis. Ang II may stimulate cleavage of EGFR proligand [72] . Facilitation of a direct physical interaction between Ang II receptors and receptor tyrosine kinase (RTK; EGFR, c-Ret) may involve clustering in lipid rafts [73] . See text for fuller description of factors crucial in UB morphogenesis and that cooperation of AT 1 R and EGFR signaling promotes the development of the renal collecting system.
Mechanisms of Ang II-growth factor interactions during UB morphogenesis
Cross-talk may be defined as a functional interaction between different signaling pathways. These interactions enhance the ability of the cell to integrate, process, and respond to the information received from its microenvironment. The consequences of cross-talks are that the expression of a given set of target genes is regulated by multiple signaling pathways. Thus, expression of the UB morphogenetic program genes and UB growth depend on complex network of regulatory pathways and signaling effectors. Angiotensin II may cross-talk with RTK and their cognate ligands via intracellular signaling pathways, the induction of cleavage of the membrane-bound RTK proligand, facilitation of physical interaction between AT 1 R/AT 2 R and RTK, or other mechanisms (see Fig. 3 ). For example, inhibition of PI3K blocks GDNF-dependent UB branching and the migration of c-Ret-transfected MDCK cells [68, 69] . Stimulation of Ang II AT 1 R activates PKC [70] , leading to MAP kinase (MAPK)-dependent upregulation of the transcription of cell-cycle progression genes, such as cyclin D1, through activation of the transcription factor AP-1 [71] . Thus, one of the possible mechanisms facilitating Ang II-EGFR/c-Ret interactions and UB morphogenesis may involve EGFR-or c-Retmediated stimulation of MAPK and PI3K/Akt pathways. Whether the effects of AT 1 R and EGFR/c-Ret result in synergistic stimulation of MAPK/PI3K and UB branching remains to be determined. AT 2 R-dependent mesenchymal apoptosis [35] may result from activation of MAP kinase phosphatase 1 leading to inactivation of ERK1/2 [51] . AT 2 R-dependent activation of Pax2 in whole metanephroi and mesenchymal cells is mediated by the JAK2/STAT pathway [64] .
Another mechanism by which Ang II may activate EGFR is by stimulating the proteolytic cleavage of proheparin-binding EGF at the cell membrane [72] . Coupling of Ang II with AT 1 R activates extracellular metalloproteinase, which cleaves the transmembrane EGF precursor and releases mature EGF [72] . Mature EGF interacts with the ectodomain of the EGFR and activates the intracellular signal. Facilitation of direct physical interaction between Ang II receptors and RTK may involve clustering in lipid rafts. For example, caveolae/lipid rafts are essential for Ang II-induced transactivation of EGFR [73] . Interestingly, EGF induces the phosphorylation of AT 1 R and leads to the formation of a multireceptor complex containing AT 1 R and activated EGFR [74] . These findings suggest that cross-talk between the RAS and RTK can be bi-directional. One mechanism whereby Ang II may transactivate RTK during UB branching is the balance between AT 1 R-and AT 2 Rmediated actions. In this regard, recent reports suggest that AT 2 R offsets the growth-promoting effects of the AT 1 R [75] and that part of the antagonism between the two receptor types may be due to the formation of AT 1 R/AT 2 R heterodimers whereby the AT 2 R directly inhibits AT 1 R [76] . Since AT 2 R expression in the metanephros progressively decreases and that of AT 1 R increases with gestation [77] , it is conceivable that increased levels of AT 1 R not complexed with AT 2 R may facilitate AT 1 R-growth factor/ RTK cross-talk to stimulate UB morphogenesis.
Future studies investigating the effect of AT 1 R and AT 2 R null mutations on the expression of the critical growth factors and signaling networks known to regulate UB branching will provide essential information on the nature of events culminating in the formation of the mature metanephros. 
